DDInter948 DDInter1002
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Ixazomib may lead to a major life threatening interaction when taken with Clozapine
Ixazomib may lead to a major life threatening interaction when taken with Rotavirus vaccine